Cytodyn

CYDY · OTC

$0.2501+$0.0001 (+0.04%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $0.25

Latest news

Press releaseOct 19, 4:50 PM ETGlobe Newswire
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
Press releaseOct 15, 8:30 AM ETGlobe Newswire
CytoDyn to Host Investor Webcast
Press releaseOct 8, 8:30 AM ETGlobe Newswire
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
Press releaseSep 1, 8:30 AM ETGlobe Newswire
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
Press releaseJul 22, 8:00 AM ETPRNewswire
Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock
Press releaseJun 11, 8:30 AM ETGlobe Newswire
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
Press releaseJun 4, 8:00 AM ETBusiness Wire
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
Press releaseJun 3, 8:30 AM ETGlobe Newswire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Press releaseMay 15, 8:30 AM ETGlobe Newswire
CytoDyn to Present at the LD Micro Invitational XVI
Press releaseMay 11, 8:30 AM ETGlobe Newswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Press releaseApr 27, 8:30 AM ETGlobe Newswire
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
Press releaseApr 23, 8:30 AM ETGlobe Newswire
CytoDyn to Host Investor Webcast
Press releaseApr 22, 8:30 AM ETGlobe Newswire
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
Press releaseApr 21, 4:10 PM ETGlobe Newswire
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
Press releaseApr 20, 8:30 AM ETGlobe Newswire
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
Press releaseApr 14, 8:30 AM ETGlobe Newswire
CytoDyn to Present at the AACR Annual Meeting 2026
Press releaseMar 24, 8:30 AM ETGlobe Newswire
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
Press releaseMar 5, 8:30 AM ETGlobe Newswire
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
Press releaseFeb 20, 8:30 AM ETGlobe Newswire
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
Press releaseJan 27, 8:30 AM ETGlobe Newswire
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
Press releaseDec 8, 8:30 AM ETGlobe Newswire
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
Press releaseDec 1, 8:30 AM ETGlobe Newswire
CytoDyn Announces Resolution of Class Action Lawsuit
Press releaseNov 24, 8:30 AM ETGlobe Newswire
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
Press releaseNov 3, 8:30 AM ETGlobe Newswire
CytoDyn Secures $30 Million Commitment from Yorkville Advisors
Press releaseOct 22, 3:56 PM ETBusiness Wire
Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights
NewsMay 28, 11:43 AM ETJames Gornick
A Penny Stock To Watch In Challenging Cancer Space
Press releaseAug 12, 8:30 AM ETGlobe Newswire
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer

CytoDyn to Host Investor Webcast

CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026

CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab

Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock

CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

CytoDyn to Present at the LD Micro Invitational XVI

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer

CytoDyn to Host Investor Webcast

CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026

CytoDyn to Present at the AACR Annual Meeting 2026

CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer

CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium

CytoDyn Announces Resolution of Class Action Lawsuit

CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium

CytoDyn Secures $30 Million Commitment from Yorkville Advisors

Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights

A Penny Stock To Watch In Challenging Cancer Space

CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer